A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
Palabras clave :
Coltuximab ravtansine
Anti-CD19 antibody drug conjugate
SAR3419
Diffuse large B-cell lymphoma
Fecha de publicación :
2018
ISSN :
0390-6078
1592-8721
Nota editorial :
© 2023 by the Ferrata Storti
Cita:
Canales-Albendea, M. A. (Miguel Ángel); Trneny, M. (Marek); Verhoef, G. (Gregor); et al. "A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy". Haematologica. 103 (8), 2018, 1351 - 1358
Aparece en las colecciones:
Estadísticas e impacto
0 citas en
0 citas en
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.